{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-oral/management/adults-young-people-not-immunocompromised/","result":{"pageContext":{"chapter":{"id":"462896e2-aa8a-5693-80bc-cb11b1d29ef2","slug":"adults-young-people-not-immunocompromised","fullItemName":"Scenario: Adults and young people (not immunocompromised)","depth":2,"htmlHeader":"<!-- begin field 8e34973a-7741-4951-ac9d-6b1cb9340091 --><h2>Scenario: Adults and young people (not immunocompromised)</h2><!-- end field 8e34973a-7741-4951-ac9d-6b1cb9340091 -->","summary":"Covers the management of oral candidiasis in people aged 16 years or older who are not markedly immunocompromised, including people who have diabetes, use inhaled corticosteroids, or wear dentures.","htmlStringContent":"<!-- begin item ff38e64c-3ccb-4fc4-9f1f-e3d12d86fd9a --><!-- begin field 69477eb1-8541-476c-b130-acbd00879c7a --><p>From age 16 years onwards.</p><!-- end field 69477eb1-8541-476c-b130-acbd00879c7a --><!-- end item ff38e64c-3ccb-4fc4-9f1f-e3d12d86fd9a -->","topic":{"id":"0f1d88eb-55a0-530e-a259-eb14f0dda14a","topicId":"b0c376a4-6364-437c-b2b0-0b37c1f9457c","topicName":"Candida - oral","slug":"candida-oral","lastRevised":"Last revised in September 2019","chapters":[{"id":"18d6ae12-7e70-5db1-bc04-693d5cb239d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5e30b9ac-9bad-5d72-95a0-522910be9b02","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a6e1a973-1e09-50e9-884c-3320ada5f64a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e89a359d-f797-5ff2-a94a-511199763a4b","slug":"changes","fullItemName":"Changes"},{"id":"e3aa3dcf-265b-5bf3-8920-86af41a82b81","slug":"update","fullItemName":"Update"}]},{"id":"1c10a9c3-b22e-5e15-9f5e-fd1b321eda87","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2044b7f8-9a22-580a-a6ee-d09f8e57e822","slug":"goals","fullItemName":"Goals"},{"id":"a2a6fc92-6ee5-5340-8de6-99645565cff9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3d375136-1f32-5b18-bfaa-072565762749","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5055e999-d687-5080-a905-6d314ff96a68","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7974345e-7b16-5e65-be63-f0b8a60779ef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19434a87-22cd-57f9-9507-fa3784bc88e9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52cafe43-224c-5c66-934b-d40eb1b71de5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"372003e6-a514-5b66-8e01-c0c4c24fcf84","slug":"definition","fullItemName":"Definition"},{"id":"6209fe71-2228-5859-966c-9dbcca7da121","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"543a3d8a-2699-5ab1-8d60-91f808bddfdf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f317e3a4-4b69-5c95-9d13-c551a893ac44","slug":"complications","fullItemName":"Complications"},{"id":"a19dd915-bb50-52c5-94e7-3c7f215a0ac3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8b32d0b5-0a06-58dc-9e26-cd5930c9b82e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e6f234d8-47d7-5740-8739-58962c6c3a1c","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"f276724c-839b-5e50-9ed1-f685c12b1c5a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"32ef3be0-0861-5c08-932e-c4295def32b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"4dbdf8e9-97b5-54f2-8023-94e3da894f99","slug":"children-not-immunocompromised","fullItemName":"Scenario: Children (not immunocompromised)"},{"id":"462896e2-aa8a-5693-80bc-cb11b1d29ef2","slug":"adults-young-people-not-immunocompromised","fullItemName":"Scenario: Adults and young people (not immunocompromised)"},{"id":"10d79010-5f47-51a1-be04-e6086178a3da","slug":"adults-immunosuppressive-treatment","fullItemName":"Scenario: Adults (immunosuppressive treatment)"},{"id":"13250ef8-0c39-5e07-b367-3b38fab47e57","slug":"adults-hiv-positive","fullItemName":"Scenario: Adults (HIV positive)"}]},{"id":"800e543f-aa34-535b-982f-b67228787534","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"50f16582-74d2-54ab-82c2-4d34b643efbd","slug":"miconazole-oral-gel","fullItemName":"Miconazole oral gel"},{"id":"52caf1d3-9e52-581c-aa51-d6c5e0d34239","slug":"nystatin-suspension","fullItemName":"Nystatin suspension"},{"id":"eaecb9ab-d5ac-5b61-b987-ed97a3b933fd","slug":"fluconazole-oral","fullItemName":"Fluconazole - oral"}]},{"id":"9d6aa898-2416-5c14-92f0-effd8eee476e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aefe3a29-b255-5d42-81cf-2ec2c53a1d28","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f1d318f6-b308-52db-a6ef-c314467ec43f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4b0b04f2-6c79-5699-8121-895467604792","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"545d5c41-fb5a-5561-9a76-8cf64fe0b179","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"098d8b0b-527b-57aa-b706-e69ada6b04fd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e055ac7-10af-5a82-b3ff-1d1c789b3c91","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4e3093df-a561-5cba-84a5-99f5890a58a5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"32ef3be0-0861-5c08-932e-c4295def32b8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"b0dd3adc-a14b-50ce-9c0b-948a98851e99","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field f852a69e-4e14-4ea1-8428-234d980b44f0 --><h3>How should I manage oral candidiasis in a person aged 16 years or older who is not immunocompromised?</h3><!-- end field f852a69e-4e14-4ea1-8428-234d980b44f0 -->","summary":null,"htmlStringContent":"<!-- begin item 681658a1-c202-479f-a9fb-1ce04b2c5ac6 --><!-- begin field 6909491b-2374-4f8d-a99d-7c0e4252aa6d --><p><strong>Admit the person if:</strong></p><ul><li>There is evidence of <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/background-information/complications/\">systemic illness</a> (candidaemia).</li><li>There is widespread infection (such as oesophageal candidiasis, characterized by difficulty or pain on swallowing, or retrosternal pain).</li></ul><p><strong>If the person can be managed in primary care:</strong></p><ul><li><strong>Exclude <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/background-information/causes-risk-factors/\">risk factors</a> for oral candidiasis, </strong>such as diabetes and haematinic deficiencies.<ul><li>Oral candidiasis is uncommon in people other than infants, denture wearers, and the elderly. In otherwise healthy people, it may be the first presentation of an undiagnosed risk factor.</li></ul></li><li><strong>Prescribe antifungal treatment.</strong><ul><li><strong>If the infection is mild and localized,</strong> prescribe topical antifungal treatment for 7 days.<ul><li>Offer miconazole oral gel first-line.</li><li>If miconazole is unsuitable, offer nystatin suspension.</li><li>See the prescribing information sections on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/miconazole-oral-gel/\">Miconazole oral gel</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/nystatin-suspension/\">Nystatin suspension</a> for information on prescribing these treatments, including contraindications, cautions, adverse effects, and possible drug interactions.</li></ul></li><li><strong>If the infection is extensive or severe infection, </strong>consider one of the following: <ul><li>Prescribe oral fluconazole 50 mg a day for 7 days. See the prescribing information section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/fluconazole-oral/\">oral fluconazole</a> for information on prescribing this treatment.</li><li>Seek specialist advice or refer to an oral surgeon.</li></ul></li></ul></li><li><strong>Give appropriate lifestyle advice to aid healing and prevent recurrence. </strong>In particular:<ul><li>Advise on good dental hygiene.</li><li>If the person is a smoker, offer advice on smoking cessation. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a> for detailed information.</li><li>If the person is using an inhaled corticosteroid, advise the following: good inhaler technique; rinsing the mouth with water (or cleaning the teeth) after inhalation, to remove any drug particles; using a spacer device to reduce the impaction of particles in the oral cavity; and stepping down the dose of inhaled corticosteroid when appropriate.<ul><li>See the section on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-inhaled/management/corticosteroids-inhaled/#minimizing-adverse-effects\">Minimizing&nbsp;the risks of adverse effects</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-inhaled/\">Corticosteroids - inhaled</a> for more information. </li></ul></li><li>If the person wears dentures, advise them to:<ul><li>Leave the dentures out for at least 6 hours in each 24-hour period to promote healing of the gums. If the gums are inflamed, they may benefit from the dentures being left out for longer.</li><li>Clean dentures by brushing and then soaking them in a disinfectant solution (for example chlorhexidine or hexetidine) overnight. The dentures can be soaked in any solution marketed to sterilize baby's bottles (providing the dentures contain no metal).</li><li>Allow the dentures to air-dry after disinfection — this also kills adherent<em> Candida</em>.</li><li>Brush the mucosal surface regularly with a soft brush.</li><li>See a dentist to correct ill-fitting dentures.</li></ul></li><li>If the person has diabetes,<strong> </strong>review diabetic control and manage accordingly, particularly if there are recurrent episodes of oral candidiasis. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a> for detailed information.<ul><li>For people taking a sulphonylurea (such as gliclazide), be aware of drug interactions with <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/miconazole-oral-gel/\">miconazole</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/fluconazole-oral/#drug-interactions\">fluconazole</a>.</li></ul></li></ul></li><li><strong>Follow up people who have extensive or severe oral candidiasis (requiring oral fluconazole) after 7 days. </strong><ul><li><strong>If the infection has completely resolved,</strong> stop treatment.</li><li><strong>If the infection has not completely resolved, </strong>consider the following: extend the course of fluconazole for a further 7 days (refer to an oral surgeon if the infection persists after this); swab to identify the causative organism; seek specialist advice; or refer to an oral surgeon — use clinical judgement, taking into account the severity of infection (there should be a low threshold for early referral if infection is severe), the level of immunocompromise, and the response to treatment. </li></ul></li><li><strong>Also consider referring to an oral surgeon (or seeking specialist advice) if:</strong><ul><li>The person has recurrent episodes of oral candidiasis.</li><li>The person has breakthrough candidal infection while receiving preventive treatment (which may indicate candidal resistance).</li><li>There is doubt about the diagnosis. </li></ul></li><li><strong>Consider referring for biopsy</strong> people with <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/diagnosis/diagnosis/\">chronic plaque-like oral candidiasis</a> that is unresponsive to treatment, as it carries a risk of malignancy.</li></ul><!-- end field 6909491b-2374-4f8d-a99d-7c0e4252aa6d --><!-- end item 681658a1-c202-479f-a9fb-1ce04b2c5ac6 -->","subChapters":[{"id":"0a970199-11d4-5d57-ba25-95193c9cdcb7","slug":"basis-for-recommendation-11d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1d47b298-ae7a-4ccf-b252-5917c2ef7878 --><h4>Basis for recommendation</h4><!-- end field 1d47b298-ae7a-4ccf-b252-5917c2ef7878 -->","summary":null,"htmlStringContent":"<!-- begin item 11d5e427-081f-4b68-9ed4-946fecd14e0c --><!-- begin field 428a9b5c-c818-4a73-a268-52c47005f1b2 --><p>These recommendations are based on expert opinion in the guidelines <em>Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Pappas, 2016</a>] and <em>Management of acute dental problems: guidance for healthcare professionals </em>published by the<em> </em>Scottish Dental Clinical Effectiveness Programme (SDCEP) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">SDCEP, 2013</a>], the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>], review articles on oral infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Ellepola and Samaranayake, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Akpan and Morgan, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Soysa et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Gonsalves et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Su et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Laudenbach and Epstein, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Coronado-Castellote, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Garcia-Cuesta, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Singh, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Patil, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BMJ, 2017</a>], and a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Hay and Ashbee, 2010</a>].</p><h5>Admission</h5><ul><li>This recommendation is based on the fact that systemic/invasive candidiasis is a significant cause of morbidity and mortality. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/background-information/complications/\">Complications</a> for more information.</li></ul><h5>Excluding risk factors</h5><ul><li>Oral candidiasis is common in infants, but in adults and older children, it may signify immune deficiency or other illness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Hoppe, 1997a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Gonsalves et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Hay and Ashbee, 2010</a>]. CKS, therefore recommends excluding risk factors in an otherwise healthy person with oral candidiasis.</li><li>Expert opinion in a review article is that the treatment of oral candidiasis should include recognizing and eliminating the underlying causes, such as ill-fitting oral appliances, history of medications (such as antibiotics and corticosteroids), immunological and endocrine disorders, and nutritional deficiency [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Patil, 2015</a>].</li></ul><h5>Antifungal treatments</h5><ul><li><strong>Miconazole</strong> has a broad spectrum of activity against fungal and yeast species [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>].<ul><li>A systematic review and meta-analysis assessed the efficacy and safety of miconazole for oral candidiasis and found that it was more effective than nystatin for thrush, and seemed to be more effective than other formulations with regard to long-term results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Zhang, 2016</a>]. However, the authors concluded that future studies that are adequately powered, large-scale, and well-designed are needed to provide higher-quality evidence for the management of oral candidiasis (17 trials were included in this review, but most were considered to have a high or moderate level of bias).</li><li>Despite the general lack of evidence from randomized controlled trials (RCTs) to support the use of topical miconazole in the treatment of oral candidiasis in otherwise healthy adults and young people, its use is supported by pharmacological principles, historical use, and extrapolation of clinical data from trials in other groups (such as infants and people who are immunosuppressed).</li></ul></li><li><strong>Nystatin</strong> suspension is not absorbed from the gastrointestinal tract and is applied locally to the mouth for treating local fungal infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]. <ul><li>There is a lack of evidence from RCTs to support the effectiveness of nystatin suspension in the treatment of oral candidal infection in otherwise healthy adults and young people. However, data extrapolated from trials in infants and immunosuppressed people suggest that it is not as effective as topical miconazole or fluconazole and is therefore not suitable as first-line treatment.</li></ul></li><li><strong>Fluconazole</strong> has a broad range of antifungal activity, including against <em>Candida</em> species [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>]. It is given orally for infections that do not respond to topical treatment (or when topical treatment cannot be used) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>], and it may be necessary for people with moderate to severe disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">SDCEP, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Patil, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Pappas, 2016</a>].<ul><li>Although there is a lack of evidence from RCTs to show the efficacy of oral fluconazole in otherwise healthy adults and young people with oral candidiasis, azole antifungals have been historically used for this purpose, and data extrapolated from trials in infants and immunosuppressed people suggest it is an effective option.</li><li>Fluconazole is not routinely recommended for first-line treatment of mild and localized candidiasis because its use is associated with increasing levels of candidal resistance (especially <em>C. glabrata </em>and <em>C. krusei</em>) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Laudenbach and Epstein, 2009</a>]. In addition, it is systemically absorbed and may cause adverse effects.</li><li>The recommended dose and duration of fluconazole are based on the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>].</li></ul></li></ul><h5>Lifestyle advice</h5><ul><li>These recommendations are based on the fact that poor dental hygiene, inhaled corticosteroids, the use of dentures, smoking, and diabetes are risk factors for oral candidiasis. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/background-information/causes-risk-factors/\">Risk factors</a> for more information.<ul><li>In addition for dentures:<ul><li>Expert opinion in a guideline is that for the management of denture-related candidiasis, disinfection of the denture, in addition to antifungal treatment, is recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Pappas, 2016</a>].</li><li>A small, open-label, comparative RCT in 61 people found that twice-daily rinses with the antiseptic hexetidine resulted in a significant reduction in the amount of <em>C. albicans </em>present in saliva, compared with pretreatment levels (no control group was included) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Koray et al, 2005</a>].</li><li>Expert opinion in review articles is that chlorhexidine is an antiseptic with a broad-spectrum activity, including antimycotic activity against <em>Candida</em> species. It can be used as an effective disinfectant for dentures, and it inhibits adhesion of <em>Candida</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Ellepola and Samaranayake, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Garcia-Cuesta, 2014</a>].</li></ul></li><li>In addition for diabetes, most experts agree that good control of blood glucose is important in the long-term management of oral candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Soysa et al, 2006</a>]. This will also have other wide-reaching benefits.</li></ul></li></ul><h5>Follow up and managing treatment failure</h5><ul><li>CKS considers that it is reasonable to follow up people with extensive or severe candidiasis to ensure the infection has cleared and complications have not developed.</li><li>Expert opinion in a review article is that if initial treatment is not fully effective, extending treatment duration is a reasonable option before expert advice or referral are sought [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>]. CKS recommends using clinical judgement to decide whether to give another course of fluconazole, swab to identify the causative organism, seek specialist advice, or refer to secondary care, taking into account the severity of infection, the level of immunocompromise, and the response to treatment. <ul><li>The recommendation to consider swabbing is based on expert opinion in a review article, which states that microbiological techniques are required when the clinical diagnosis needs to be confirmed, for establishing a differential diagnosis, and in cases characterized by resistance to antifungal treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Coronado-Castellote, 2013</a>].</li></ul></li></ul><h5>Referral or seeking specialist advice</h5><ul><li>The BNF recommends referral for investigation if candidal infection fails to respond to 1–2 weeks of antifungal treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]. Oral candidiasis is rare in otherwise healthy adults and young people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Hoppe, 1997a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Hay and Ashbee, 2010</a>], and widespread or severe infection may require further assessment by a specialist.</li><li>Expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Coronado-Castellote, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Singh, 2014</a>] and the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>] is that biopsies are indicated in people with hyperplastic candidiasis, due to the increased risk of malignancy.</li></ul><h5>Treatments not recommended </h5><ul><li><strong>Oral itraconazole </strong>should be reserved for cases of fluconazole-resistant candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]. Specialist advice should be obtained before initiating itraconazole treatment because of the increased risk of drug interactions and adverse effects.</li><li><strong>Oral ketoconazole </strong>should no longer be prescribed for the treatment of fungal infections as the risk of liver damage outweighs the benefits. For this reason, the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has suspended its marketing authorisation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">MHRA, 2013</a>]. See the <a href=\"http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON297530\" data-hyperlink-id=\"db99fec4-79b3-4059-8245-a98d012c4ede\">MHRA website</a> for more information.</li><li><strong>Oral amphotericin </strong>is not recommended as there is a lack of trial evidence of efficacy in the treatment of oral candidiasis. It is sometimes used as an adjunct to other systemic antimycotic drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Laudenbach and Epstein, 2009</a>].</li></ul><!-- end field 428a9b5c-c818-4a73-a268-52c47005f1b2 --><!-- end item 11d5e427-081f-4b68-9ed4-946fecd14e0c -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}